Arcutis Biotherapeutics Inc. (ARQT)
ARQT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/0001787306-26-000018-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ARQT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001787306 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $376.1M |
| Net income | -$16.1M |
| Operating income | -$12.2M |
| Net margin | -4.3% |
| Operating margin | -3.3% |
| Revenue growth | +91.3% |
| Cash | $42.9M |
| Total assets | $433.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $33.4M cash; operating cash flow $15.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 126,455,033 (2026-10-30); 122,492,192 a year earlier; 94,382,074 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-11-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Los Angeles, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $17.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $143.9M | $8.8M | $18.9M | $33.4M | $109.4M | $508.7M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $129.9M | $15.0M | $12.6M | $34.1M | $108.9M | $464.0M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $105.4M | -$11.3M | $2.2M | $34.8M | $109.4M | $415.6M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $129.5M | $17.4M | $26.2M | $42.9M | $109.0M | $376.1M | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $99.2M | $7.4M | -$1.8M | $47.1M | $108.5M | $317.9M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $81.5M | -$15.9M | $324K | $72.7M | $108.0M | $263.5M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $65.8M | -$25.1M | -$30.4M | $53.1M | $107.6M | $212.8M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $71.4M | -$10.8M | -$748K | $71.3M | $107.2M | $196.5M | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-04 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 868 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +10.6% |
| 1 month | +8.3% |
| 3 months | +9.4% |
| Year to date | -2.7% |
| 1 year | +23.6% |
| From 52-week high | -17.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VKTX | Viking Therapeutics Inc. | $26.80 | -8.28% | $3.4B |
| VRDN | Viridian Therapeutics Inc. | $29.80 | -3.47% | $3.4B |
| IRON | Disc Medicine Inc. | $76.59 | -4.26% | $3.5B |
| ELVN | Enliven Therapeutics Inc. | $47.62 | -2.42% | $3.5B |
| PBLS | Parabilis Medicines Inc. | $28.45 | +0.07% | $3.5B |
| AMLX | Amylyx Pharmaceuticals Inc. | $27.80 | -8.22% | $3.6B |
| ABCL | AbCellera Biologics Inc. Common Shares | $11.12 | -3.22% | $3.6B |
| OGN | Organon & Co. Common Stock | $13.90 | 0.00% | $3.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier